Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-1,99
KB0,90
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
28.03.2024 21:30:00
Indexy online
AD Index online
select
AD Index online
 

  • 15.03.2024 22:20:00
Boiron SA (BOIRF.PK, US Other OTC (Pink Sheets))
Závěr k 15.3.2024 Změna (%) Změna (USD) Objem obchodů (ks)
35,79 -6,97 -2,68 100
After-hours15.03.2024 22:20:00
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
35,79 - - -6,97 -2,68
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.03.2024
Popis společnosti
Obecné informace
Název společnostiBoiron SA
TickerBOI
Kmenové akcie:Ordinary Shares
RICBOIR.PA
ISINFR0000061129
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky30.09.2023
Počet zaměstnanců k 30.06.2023 2 813
Akcie v oběhu k 30.06.2023 17 362 183
MěnaEUR
Kontaktní informace
Ulice2 avenue de l ouest Lyonnais
MěstoRONTALON
PSČ69510
ZeměFrance
Kontatní osobaFabrice Rey
Funkce kontaktní osobyHead of Investor Relations
Telefon33 478 456 100
Fax33478456291
Kontatní telefon33 478 456 100

Business Summary: Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Boiron SA revenues decreased 7% to EUR239.9M. Net income increased 24% to EUR15.5M. Revenues reflect Other segment decrease of 66% to EUR15.4M, Non-Proprietary Homeopathic Medicines segment decrease of 2% to EUR87.5M, France segment decrease of 20% to EUR112.5M. Net income reflects North America segment income totaling EUR1.6M vs. loss of EUR179K.
Odvětvová klasifikace
TRBC2012Alternative Medicine
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 28.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the BoardThierry Boiron6115.12.2004
Chief Executive Officer, General Manager, DirectorValerie Lorentz-Poinsot5301.01.201901.07.2011
Deputy Chief Executive Officer, Deputy General Manager, Chief Pharmacist, Pharmaceutical Development DirectorJean-Christophe Michel Bayssat5901.01.201601.01.2016